Dr. Findley’s medical and executive experience is deeply aligned with ACLM’s vision to combat chronic disease through evidence-based, lifestyle-centered interventions. Hailing from Bentonville, Arkansas, he has committed more than twenty years to pioneering integrative approaches that prioritize chronic disease prevention, population health management, and interdisciplinary collaboration. His work underscores the necessity of synchronizing patient-centered care strategies with innovative health system redesign, ultimately striving for improved patient outcomes alongside reduced healthcare burdens. Since becoming an ACLM member in 2007, Dr. Findley has remained closely aligned with the College’s objectives.

As elucidated by ACLM President Padmaja Patel, MD, the selection of Dr. Findley reflects a careful and strategic effort to identify a leader who embodies both clinical insight and a visionary operational mindset. Dr. Patel emphasized Dr. Findley’s profound grasp of patient care realities combined with his ability to navigate complex healthcare systems. Under his stewardship, lifestyle medicine is poised to evolve from a specialized domain into a transformative force that reshapes healthcare delivery and reimbursement frameworks nationwide.

Dr. Findley’s professional journey encompasses significant roles, including his most recent position as Chief Medical Officer at the Heartland Whole Health Institute. Within this capacity, he facilitated collaborative initiatives involving health systems, employers, payers, and government entities. These partnerships focused on the large-scale implementation of lifestyle medicine approaches chiefly targeting chronic disease reversal and prevention, grounded in rigorous clinical and behavioral sciences.

He is the founding force behind LifeworRx, a comprehensive model integrating lifestyle medicine principles to reverse chronic diseases by modifying behavioral and environmental determinants. Additionally, his work with KidwoRxs highlights a commitment to preventive health in younger populations, extending lifestyle medicine’s reach through school-based wellness and prevention programming. This breadth of involvement from clinical weight management to behavioral coaching in rehabilitation settings illustrates his holistic grasp of lifestyle medicine’s practical application across diverse patient populations.

Dr. Findley’s leadership style is characterized by fostering collaborative, patient-centered care innovations that align prevention, behavior modification, and value-based care delivery. These integrated frameworks are critical for producing meaningful, sustainable improvements in healthcare quality and cost-effectiveness. His ability to harmonize clinical expertise with system-level transformation initiatives exemplifies the future direction of lifestyle medicine — one that is deeply embedded within mainstream healthcare strategies.

In his own remarks, Dr. Findley expressed profound enthusiasm for leading ACLM at this juncture, recognizing the College’s foundational role in establishing lifestyle medicine as an evidence-based standard for addressing chronic conditions. He underscored that the movement’s future lies not merely in validating lifestyle medicine efficacy, but in ensuring its widespread adoption across all healthcare settings, thereby reshaping care paradigms and health outcomes on a national scale.

Under Dr. Findley’s guidance, ACLM will intensify efforts in advancing the College’s strategic priorities, encompassing clinical care innovations, educational initiatives, research advancements, and policy advocacy. His leadership aims to bolster ACLM’s expanding portfolio of programs and partnerships, enhancing the organization’s presence as a key influencer in the evolving healthcare ecosystem committed to whole-person, lifestyle-informed care models.

This leadership transition follows the distinguished tenure of former CEO Susan Benigas, who has transitioned to a CEO emeritus and senior advisory role after more than a decade of transformative stewardship. Benigas’s era was marked by remarkable growth, expanding ACLM’s membership to over 16,000 professionals and firmly establishing its preeminence as an authoritative voice in lifestyle medicine. Her commitment and vision laid the groundwork upon which Dr. Findley will build.

Benigas expressed confidence in Dr. Findley’s capacity to amplify ACLM’s mission, emphasizing the synergy between his physician leadership and operational acumen. She also pledged ongoing support during the leadership handover, signaling a seamless continuity as ACLM seeks to entrench lifestyle medicine as the national and global standard of care.

Founded in 2004, ACLM has emerged as the primary medical professional society championing lifestyle medicine as an indispensable foundation for an equitable and value-based healthcare delivery system. It is dedicated to eradicating the root causes of chronic diseases by optimizing modifiable risk factors through education, advocacy, certification, and practice transformation. Currently representing a diverse membership of healthcare providers, ACLM has delivered over 1.2 million hours of lifestyle medicine education, addressing a critical gap in conventional medical training.

ACLM’s philosophy encapsulates the Quintuple Aim, emphasizing not just healthcare quality and cost, but also population health equity, patient experience, clinician well-being, and systemic sustainability. This comprehensive approach defines the organization’s strategic imperatives as it navigates the complexities of healthcare reform and chronic disease epidemics through scalable lifestyle interventions.

In conclusion, Dr. John Findley’s appointment as CEO heralds a transformative era for the American College of Lifestyle Medicine. With his seasoned expertise at the interface of clinical care, health system innovation, and population health, ACLM is uniquely positioned to scale the impact of lifestyle medicine from a specialized field to a universal standard. The next chapter entails translating robust scientific evidence into actionable, community-wide solutions that redefine health for generations, addressing chronic disease not solely through pharmaceuticals or procedures, but through sustainable lifestyle change embedded in every facet of care.

Subject of Research: Lifestyle Medicine and Healthcare Transformation
Article Title: Dr. John Findley Appointed CEO of the American College of Lifestyle Medicine, Ushering in a New Era of Whole-Person Healthcare
News Publication Date: Not specified
Web References: https://lifestylemedicine.org
Image Credits: ACLM
Keywords: Lifestyle Medicine, Chronic Disease Prevention, Healthcare Transformation, Value-Based Care, Whole-Person Health, Population Health, Health System Redesign, Patient-Centered Care, Clinical Leadership, Medical Professional Society, Healthcare Innovation, Evidence-Based Medicine

This pioneering symposium was designed with the vision to drive forward biomedical innovation through cross-disciplinary dialogue and global partnership. It served as a catalyst for nurturing collaborative research networks that address pervasive human health concerns such as climate change-related health effects, emerging infectious diseases, and persistent global health disparities. The event was more than a gathering; it was a concerted effort to harness diverse academic expertise and clinical insights to forge a future where science directly benefits humanity.

The intense opening session, overseen by Professor Sun Wook Hwang, Vice Dean of Research, plunged into “Therapeutic Mechanisms for Clinical Translation.” Distinguished presentations explored the molecular and cellular pathways involved in hepatocellular carcinoma progression, highlighting the urgent need for novel therapeutic approaches. Additionally, the discussion illuminated the promise held by low-cost, natural product-derived treatments intended particularly for resource-limited settings, underscoring the global imperative of equitable healthcare solutions. Speakers such as Professor Henry Chan from The Chinese University of Hong Kong and Professor Olaniyan Tope of Nigeria’s Kwara State University led these discussions, integrating clinical research with practical application considerations.

The symposium’s second theme, “Biomedical Convergence for Global Healthcare,” chaired by Professor Sung Gu Kang from the Korea University Anam Hospital’s Department of Urology, underscored the transformative potential of integrating engineering, molecular biology, and clinical medicine. Among the diverse topics discussed were international cooperative efforts in prostate cancer research and the intricate vascular biology underlying disease pathogenesis. Contributors included leading figures such as Professor Isaac Kim of Yale School of Medicine and Professor Hanjoong Jo of Georgia Tech. Their work demonstrated how converging disciplines can accelerate innovative drug development and enhance strategies for combating complex diseases on a global scale.

Broadening the scope, the third session—“Integration of Health Policy & Human Behaviors,” under the leadership of Professor Eunsoo Choi from the Department of Psychology—examined the interplay between policy frameworks, behavioral sciences, and epidemiology. Presentations delved into cardiovascular risk factor management strategies influenced by psychosocial determinants, spatial social psychology’s role in community health, resilience mechanisms to climate-change-induced pandemics, and cutting-edge research in human virology. Esteemed scholars such as Professor Lentflow from the University of Cambridge and Professor Waheed from Pakistan’s National University of Sciences and Technology contributed insights that meld policy analysis with behavioral health to optimize preventive and therapeutic interventions worldwide.

Korea University’s faculty members across a broad spectrum of basic and clinical science disciplines actively engaged in the symposium, enriching the discourse through their expertise. Vice Dean of Academic Affairs Hyeon Soo Kim (Department of Anatomy), Professor Man-Seong Park (Microbiology), and Professor Jee Hoon Roh (Physiology) participated in dynamic sessions. Clinical specialists including Professor Sung-soo Park (Surgery), Professor Ki Jin Ryu (Obstetrics and Gynecology), Professor Jinwoo Park (Neurology), and Professor Sun Young Yim (Gastroenterology) contributed critical perspectives that bridged foundational science with patient-centered care. Their involvement highlighted the institution’s commitment to holistic biomedical education and research.

Graduate students also played a pivotal role in the symposium by presenting posters and engaging in interactive discussions. This inclusion demonstrated the academic vigor of Korea University’s medical community and its dedication to fostering the next generation of physician-scientists and biomedical researchers. Their participation ensured that emerging ideas and fresh perspectives influenced ongoing dialogues about advancing human health through innovation and collaboration.

In his keynote address, Dean Seong Bom Pyun articulated a compelling vision for Korea University College of Medicine. Emphasizing the dismantling of disciplinary and geographic silos, he underscored the necessity of multidisciplinary, international partnership to effectively confront global health crises. Dean Pyun acknowledged the invaluable contributions from partner institutions including Yale School of Medicine and the National University of Singapore School of Medicine. These collaborations aim to cultivate highly skilled physician-scientists and expand student exchange initiatives, thereby creating a fertile environment for shared knowledge and resources.

The event’s conclusion featured remarks from Dean Jae-yong Park of the College of Health Science, who expressed hope that the K-CLUB platform would stimulate ongoing knowledge exchange and propel innovations in healthcare both within Korea and internationally. He anticipated that the rich discussions from this inaugural symposium would translate into concrete collaborative research efforts, fostering tangible improvements in clinical practice and biomedical technology.

Looking to the future, Korea University College of Medicine intends to leverage the momentum generated by the K-CLUB International Symposium to solidify its position as a leading global research institution. The college plans to deepen ties with distinguished scholars worldwide, advancing research agendas that intersect fundamental biological sciences, clinical innovation, and public health. This strategic expansion is poised to cultivate transformative educational programs and consolidate global biomedical research endeavors.

The K-CLUB International Symposium’s focus on integrating scientific disciplines, engaging global expertise, and emphasizing translational research represents a paradigm shift in medical symposia. It reflects a comprehensive approach to healthcare innovation—one that prioritizes equitable access, global collaboration, and the seamless translation of scientific discovery into clinical reality. This pioneering effort by Korea University College of Medicine not only enhances the institution’s international stature but also contributes meaningfully to the collective endeavor of improving human health worldwide.

Overall, this landmark event underscored the intricate complexity of current global health challenges and demonstrated how collective academic and clinical expertise can forge innovative pathways forward. The stimulating discussions, vibrant exchange of ideas, and strong institutional commitments provide an inspiring model for how universities can lead in addressing humanity’s most pressing health concerns through interdisciplinary collaboration and international partnership.

Subject of Research: Global Health Innovation and Biomedical Convergence

Article Title: Korea University College of Medicine Launches K-CLUB International Symposium to Pioneer Global Health Collaboration

News Publication Date: July 4, 2024

Web References: https://mediasvc.eurekalert.org/Api/v1/Multimedia/df4b114a-f98e-4bef-abe3-90b9b9180822/Rendition/low-res/Content/Public

Image Credits: KU Medicine

Keywords: Health and medicine, Biomedical engineering

The BeginNGS Consortium is a pioneering public-private alliance that seeks to revolutionize newborn screening practices globally. By utilizing comprehensive whole genome sequencing, it identifies infants at risk for a multitude of genetic disorders before clinical symptoms manifest. This proactive detection empowers physicians to recommend targeted therapeutic interventions at the earliest stages, potentially altering the natural progression of these diseases. The Consortium’s membership spans a broad spectrum of stakeholders whose collective expertise ranges from healthcare delivery and biotechnology to information technology and patient advocacy, underscoring an interdisciplinary commitment to advancing genome-informed medicine.

Alexion’s elevation to Platinum membership signals a deepened engagement that extends beyond financial sponsorship to strategic guidance and expert scientific collaboration. As a vanguard in rare disease therapeutics, Alexion brings over 30 years of specialized experience to the Consortium, bolstering efforts to refine diagnostic algorithms and optimize clinical workflows around newborn genomic screening. This enhanced partnership aims to scale the implementation of BeginNGS, with an ambitious goal of screening for 1,000 genetic diseases across at least ten countries by the year 2030, thereby fostering significant global health impact.

The Consortium’s approach to genome-informed newborn screening is guided by rigorous scientific validation. Recent studies published in The American Journal of Human Genetics have demonstrated the robustness of BeginNGS’s technology platform. These investigations reveal a 97 percent reduction in false-positive rates compared to conventional screening methods. Such heightened specificity not only spares families the emotional burden of diagnostic uncertainty but also curtails unnecessary follow-up testing. Moreover, BeginNGS has proven capable of diagnosing genetic diseases substantially earlier, benefiting approximately one in thirteen infants screened—an achievement unparalleled in current neonatal screening programs.

Fundamentally, BeginNGS transcends traditional newborn screening by deploying next-generation sequencing technologies capable of analyzing the entire genome at birth. This comprehensive analysis surpasses established biochemical and targeted genetic panels by detecting a broader spectrum of pathogenic variants, including rare or novel mutations. The technological sophistication ensures precise variant interpretation and prioritization, leveraging extensive genomic databases and computational tools. This approach facilitates timely clinical decision-making and the initiation of effective interventions that may delay, mitigate, or prevent the onset of debilitating disease symptoms.

The Consortium constitutes a novel ecosystem that unites leaders from healthcare delivery organizations, biopharmaceutical companies, biotech innovators, IT specialists, and patient advocacy groups. Their coordinated efforts aim to establish scalable, globally applicable infrastructure for genome-guided care, addressing the diverse logistical and ethical challenges involved in newborn genomic screening. Integral to this ecosystem is the harmonization of data sharing, standardization of interpretation pipelines, and integration of genomic findings into electronic health records, all while safeguarding patient privacy and consent.

One of the greatest challenges in implementing whole genome sequencing at a population scale lies in balancing sensitivity with specificity. The BeginNGS platform, through iterative refinement, employs sophisticated bioinformatic filters and machine learning algorithms that discern pathogenic variants from benign polymorphisms with unprecedented accuracy. This capability addresses longstanding concerns about the clinical validity and utility of genomic data in newborns, offering clinicians actionable insights that directly inform patient care pathways from the earliest possible juncture.

Interdisciplinary collaboration lies at the heart of BeginNGS’s success. By leveraging Alexion’s expertise in rare disease mechanisms and therapeutic development alongside RCIGM’s advanced genomic medicine infrastructure, the Consortium fosters an environment conducive to rapid knowledge exchange and innovation. Such alliances accelerate the translation of genomic data into tangible health outcomes, enabling the development of new diagnostics, treatment protocols, and preventative strategies that target the unique genetic etiologies of childhood diseases.

A crucial dimension of the Consortium’s work is its commitment to health equity. Rare genetic diseases impose disproportionate burdens on underserved populations who often face delays in diagnosis due to limited access to specialized testing. The expansion of BeginNGS aims to democratize genomic newborn screening globally, lowering barriers by standardizing and scaling the deployment of sophisticated genetic analyses. This vision encompasses initiatives to engage diverse healthcare systems and patient communities, ensuring that innovations in genomic medicine reach all segments of society.

The remarkable potential of BeginNGS also lies in its capacity to catalyze broader genomic research. The rich genomic datasets generated through newborn screening provide unparalleled opportunities to elucidate disease mechanisms, identify novel genetic variants, and refine genotype-phenotype correlations. This iterative knowledge generation fuels continuous improvement of diagnostic algorithms and therapeutic interventions, reinforcing the virtuous cycle of precision medicine from the earliest moments of life.

Looking ahead, the strategic involvement of Platinum member Alexion will amplify these initiatives by injecting additional resources and specialized knowledge into the Consortium’s operations. Their support extends to advisory roles, technical validation studies, and collaborative development of next-generation diagnostic technologies. This partnership exemplifies an emerging paradigm in biopharma where companies engage deeply not just in drug development, but in foundational diagnostics that enable precision health trajectories from birth.

In summation, the formalization of Alexion’s Platinum membership marks a watershed moment for BeginNGS and the broader field of genomic medicine. By harnessing state-of-the-art whole genome sequencing technology, robust data analytics, and multi-sector collaboration, the Consortium is poised to redefine newborn screening on a global scale. Their shared vision is clear: to diagnose and intervene in genetic diseases earlier than ever before, minimizing childhood morbidity and mortality while ushering in a new era of equitable, genome-informed healthcare delivery worldwide.

Subject of Research: Newborn screening through whole genome sequencing for rare genetic diseases
Article Title: Alexion Joins BeginNGS Consortium as First Platinum Member to Accelerate Global Genome-Informed Newborn Screening
News Publication Date: May 19, 2025
Web References: https://radygenomics.org/begin-ngs-newborn-sequencing/
Keywords: Genomics, Genetic testing, Whole genome sequencing, Rare genetic diseases, Newborn screening, Precision medicine, Rare disease diagnostics, Genome-informed healthcare, Pediatric genetics